Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne ...

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best biotech stocks to invest in now. On June 17, Dyne Therapeutics announced that the FDA granted Breakthrough Therapy Designation to DYNE-101 ...